Entero Therapeutics presents two posters on celiac disease research at DDW 2024

Entero Therapeutics yesterday presented two posters on celiac disease research at the 2024 Digestive Disease Week, DDW 2024, Conference in Washington, D.C. The presentations draw upon research from the robust clinical program investigating latiglutenase, an oral biotherapeutic being developed as a potentially first-in-class, targeted, oral biotherapeutic for celiac disease, CeD. The results from these presentations demonstrate potential for improved CeD diagnostics and clinical trial design. “These findings will enable us to better monitor celiac disease and refine the tools we use in its diagnosis,” said Jack Syage, Ph.D., President and Chief Scientific Officer of Entero Therapeutics. “The data that indicates significantly higher levels of gluten are required to revert serology to positive in CeD patients underscores a fundamental gap in our diagnostic capabilities.”